(R)-BI-2536

Article No SYN-1019-M050
Product Type Chemicals & Biochemicals
Research Area Cell Death
Format Powder
Size 50 mg

This product is not available for sale in your country. Please feel free to contact the help desk if you have any questions.

Specifications

CAS No 755038-02-9
MW 521.7
Country Availability DK, EE, FI, IS, LT, LV, NO, SE
Data Sheet Link https://www.adipogen.com/productmanagement/resource/download/type/sheet/id/4827
Description (R)-BI-2536
Supplier Adipogen Life Sciences
Notes Polo-like kinase 1 (Plk1) is a regulator of the cell cycle that has been implicated in the pathology of many cancers. BI-2536 is a potent and selective small-molecule inhibitor of mammalian Plk1. It has inhibitory activity at subnanomolar concentrations and inhibits tumor growth in multiple tumor lines with IC(50) values below 1µM. BI-2536 also shows an >1,000-fold selectivity for PIK1 versus a large panel of other kinases. BI-2536 also demonstrated low Kd values against sister kinases PLK2 and PLK3. Preclinical studies in human cancer cell lines have shown that BI 2536 disrupts spindle assembly, resulting in mitotic arrest and inducing apoptosis. BI-2536 is currently in clinical trials against several types of solid tumor cancers.
Molecular Formula C28H39N7O3
Alias Names (R)-BI2536
Purity >95%
References BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo: M. Steegmaier, et al.; Curr. Biol. 17, 316 (2007) | Pharmacophore modeling and virtual screening for designing potential PLK1 inhibitors: H.Y. Wang, et al.; Bioorg. Med. Chem. Lett. 18, 4972 (2008) | Hit to Lead optimization of a novel class of squarate-containing polo-like kinases inhibitors: Q. Zhang, et al.; Bioorg. Med. Chem. Lett. 22, 7615 (2012) | HDAC inhibitors increase NRF2-signaling in tumour cells and blunt the efficacy of co-adminstered cytotoxic agents: M. McMahon, et al.; PLoS One 9, e114055 (2014)
Solubility Soluble in DMSO, Ethanol
Storage -20°C
Technical Specifications Chemical. CAS: 755038-02-9. Formula: C28H39N7O3. MW: 521.7. Polo-like kinase 1 (Plk1) is a regulator of the cell cycle that has been implicated in the pathology of many cancers. BI-2536 is a potent and selective small-molecule inhibitor of mammalian Plk1. It has inhibitory activity at subnanomolar concentrations and inhibits tumor growth in multiple tumor lines with IC(50) values below 1µM. BI-2536 also shows an >1,000-fold selectivity for PIK1 versus a large panel of other kinases. BI-2536 also demonstrated low Kd values against sister kinases PLK2 and PLK3. Preclinical studies in human cancer cell lines have shown that BI 2536 disrupts spindle assembly, resulting in mitotic arrest and inducing apoptosis. BI-2536 is currently in clinical trials against several types of solid tumor cancers.
Product Page Updated 2019-01-09T14:34:57.552Z

Shipping info

The delivery time for this item is approximately 5-8 business days. If other deviations occur, this will be noted on the order confirmation or communicated via email. Please note, we do reserve the right to select the best packaging and shipping method in order to insure the stability of the product and allow efficient order tracking.

Product insert:

Product data sheet

Datasheet